The Role of Monitoring Vancomycin Levels in Patients with Peritoneal Dialysis-Associated Peritonitis

Stevenson, Sarah; Tang, Wen; Cho, Yeoungjee; Mudge, David W.; Hawley, Carmel M.; Badve, Sunil V.; Johnson, David W.

doi:10.3747/pdi.2013.00156

Cited by 22 publications

(24 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A randomized controlled trial in children found that intermittent dosing of vancomycin is as efficacious as continuous dosing ( 311 ). The role of monitoring serum vancomycin levels is controversial ( 284 , 312 ). In general, a dosing interval of every 4 to 5 days would keep serum trough levels above 15 μg/mL, but there is substantial inter-individual variability ( 284 , 304 ).…”

Section: Initial Presentation and Management Of Peritonitismentioning

confidence: 99%

ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment

et al. 2016

Self Cite

View full text Add to dashboard Cite

Section: Initial Presentation and Management Of Peritonitismentioning

confidence: 99%

ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment

et al. 2016

Self Cite

View full text Add to dashboard Cite

“…Clinical outcomes of gram‐positive and culture‐negative peritonitis were not associated with either the frequency or levels of serum vancomycin measurements in the first week of treatment when vancomycin is dosed according to International Society for Peritoneal Dialysis …”

Section: Therapeutic Drug Monitoringmentioning

confidence: 98%

“…Given equivalent TDM costs and the lack of a clear clinical benefit, the role of CI remains to be defined, in spite of practical and theoretical advantages, particularly in burn patients Patients receiving ambulatory peritoneal dialysisThe JPN guideline summarizes evidence and presents recommendations for this subpopulation (Table ).Clinical outcomes of gram‐positive and culture‐negative peritonitis were not associated with either the frequency or levels of serum vancomycin measurements in the first week of treatment when vancomycin is dosed according to International Society for Peritoneal Dialysis describes the PPK models developed for this subpopulation. …”

Section: Therapeutic Drug Monitoringmentioning

confidence: 99%

Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations

Monteiro

Hahn

Gonçalves

et al. 2018

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Vancomycin is a fundamental antibiotic in the management of severe Gram‐positive infections. Inappropriate vancomycin dosing is associated with therapeutic failure, bacterial resistance and toxicity. Therapeutic drug monitoring (TDM) is acknowledged as an important part of the vancomycin therapy management, at least in specific patient subpopulations, but implementation in clinical practice has been difficult because there are no consensus and agglutinator documents. The aims of the present work are to present an overview of the current knowledge on vancomycin TDM and population pharmacokinetic (PPK) models relevant to specific patient subpopulations. Based on three published international guidelines (American, Japanese and Chinese) on vancomycin TDM and a bibliographic review on available PPK models for vancomycin in distinct subpopulations, an analysis of evidence was carried out and the current knowledge on this topic was summarized. The results of this work can be useful to redirect research efforts to address the detected knowledge gaps. Currently, TDM of vancomycin presents a moderate level of evidence and practical recommendations with great robustness in neonates, pediatric and patients with renal impairment. However, it is important to investigate in other subpopulations known to present altered vancomycin pharmacokinetics (eg neurosurgical, oncological and cystic fibrosis patients), where evidence is still unsufficient.

show abstract

“…On the other hand, data from a single-center study involving 34 PD patients experiencing PD-related peritonitis showed no relationship between plasma vancomycin levels measured during the first week and PD-related peritonitis outcomes. 42 Here, CAPD was reportedly the most frequent modality (80%) used with an average residual creatinine clearance of 2.8 mL/min/1.73 m2. Vancomycin was dosed based on ISPD recommendations and plasma levels were maintained above 15 mg/L.…”

Section: Tdm and Pharmacodynamic Responsementioning

confidence: 82%

Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy

et al. 2020

View full text Add to dashboard Cite

Intraperitoneal vancomycin is the first-line therapy in the management of peritoneal dialysis (PD)-related peritonitis. However, due to the paucity of data, vancomycin dosing for peritonitis in patients on automated peritoneal dialysis (APD) is empiric and based on clinical experience rather than evidence. Studies in continuous ambulatory peritoneal dialysis (CAPD) patients have been used to provide guidelines for dosing and are often extrapolated for APD use, but it is unclear whether this is appropriate. This review summarizes the available pharmacokinetic data used to inform optimal dosing in patients on CAPD or APD. The determinants of vancomycin disposition and pharmacodynamic effects are critically summarized, knowledge gaps explored, and a vancomycin dosing algorithm in PD patients is proposed.

show abstract

The Role of Monitoring Vancomycin Levels in Patients with Peritoneal Dialysis-Associated Peritonitis

Cited by 22 publications

References 15 publications

ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment

ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment

Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations

Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy

Contact Info

Product

Resources

About